Sugi Predict

Sugi Predict / Compounds / SCHEMBL14796728

SCHEMBL14796728

SCHEMBL14796728

O=c1cc(O)c2ccc(Br)cc2[nH]1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDM4E B2RXH2 2/20 0.59
▸ ALDH1A1 P00352 2/20 0.59
▸ KDM5A P29375 1/20 0.53
▸ GAA P10253 2/20 0.47
▸ GLA P06280 1/20 0.47
▸ HPGD P15428 1/20 0.47
▸ METAP2 P50579 1/20 0.47
▸ GSK3A P49840 3/20 0.44
▸ GSK3B P49841 3/20 0.44
▸ CDK1 P06493 3/20 0.44
▸ CDK5 Q00535 3/20 0.44
▸ CDK5R1 Q15078 3/20 0.44
▸ CCNB2 O95067 2/20 0.44
▸ CCNB1 P14635 2/20 0.44
▸ CCNB3 Q8WWL7 2/20 0.44
▸ CA12 O43570 1/20 0.43
▸ CA1 P00915 1/20 0.43
▸ CA2 P00918 1/20 0.43
▸ CA9 Q16790 1/20 0.43
▸ PIM1 P11309 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29831055 1.00 KDM4E (0.59) KDM4EALDH1A1KDM5AGAAGLA
SCHEMBL9393238 0.89 KDM4E (0.47) KDM4EALDH1A1KDM5AGAAGLA
SCHEMBL2054683 0.85 ALDH1A1 (0.59) KDM4EALDH1A1KDM5AHPGDGSK3A
SCHEMBL29892996 0.79 KDM4E (0.62) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL2798886 0.79 KDM4E (0.62) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL9160411 0.78 CHEK1 (0.49) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL8109985 0.78 KDM4E (0.59) KDM4EALDH1A1KDM5AGAAGLA
SCHEMBL29171685 0.78 TP53 (0.47) KDM4EALDH1A1GAAGLAHPGD
SCHEMBL8127333 0.78 TP53 (0.66) KDM4EALDH1A1KDM5AGAAGLA
SCHEMBL30759515 0.78 TP53 (0.47) KDM4EALDH1A1GAAGLAHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250325687-A1 CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST MABSOFT THERAPEUTICS SHANGHAI CO LTD (CN) 2025-10-23 — — US disclosed
US-20240199613-A1 POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN TAKEDA PHARMACEUTICALS CO (JP) 2024-06-20 — — US disclosed
EP-4313308-A1 TEAD INHIBITORS AND USES THEREOF Cedilla Therapeutics, Inc. (US) 2024-02-07 — — EP disclosed
EP-4308564-A1 POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN Takeda Pharmaceutical Company Limited (JP) 2024-01-24 — — EP disclosed
CN-117355523-A Polycyclic inhibitors of plasma kallikrein 武田药品工业株式会社 2024-01-05 — — CN disclosed
US-20230098872-A1 TEAD INHIBITORS AND USES THEREOF CEDILLA THERAPEUTICS, INC. 2023-03-30 — — US disclosed
WO-2022204452-A1 TEAD INHIBITORS AND USES THEREOF CEDILLA THERAPEUTICS, INC. (US) 2022-09-29 — — WO disclosed
WO-2022197789-A1 POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN SHIRE HUMAN GENETIC THERAPIES, INC. (US) 2022-09-22 — — WO disclosed
EP-3247705-B1 QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF AS NAMPT INHIBITORS MILLENNIUM PHARM INC (US) 2019-11-20 — — EP disclosed
EP-3247705-B1 QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF AS NAMPT INHIBITORS MILLENNIUM PHARM INC (US) 2019-11-20 — — EP disclosed
US-10323018-B2 Quinazoline and quinoline compounds and uses thereof MILLENNIUM PHARMACEUTICALS, INC. (US) 2019-06-18 — — US disclosed
US-20180009784-A1 QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. 2018-01-11 — — US disclosed
EP-3247705-A1 QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF Millennium Pharmaceuticals, Inc. (US) 2017-11-29 — — EP disclosed
EP-2760841-B1 PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI SA (FR) 2016-08-24 — — EP disclosed
WO-2016118565-A1 QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-28 — — WO disclosed
WO-2016118565-A1 QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF MILLENNIUM PHARMACEUTICALS, INC. (US) 2016-07-28 — — WO disclosed
EP-2573073-B1 Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof SANOFI SA (FR) 2014-10-22 — — EP disclosed
US-20140235616-A1 PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF SANOFI (FR) 2014-08-21 — — US disclosed
CN-103958479-A Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof SANOFI SA 2014-07-30 — — CN disclosed
EP-2573073-A1 Pyrazoloquinolinone derivatives, preparation thereof and therapeutic use thereof SANOFI (FR) 2013-03-27 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230098872-A1 TEAD INHIBITORS AND USES THEREOF TEAD2, TEAD3, TEAD4 KDM4E 1730/4885ALDH1A1 1319/4885KDM5A 2694/4885
US-20240199613-A1 POLYCYCLIC INHIBITORS OF PLASMA KALLIKREIN KLKB1, KLK1, KLK5 KDM4E 794/4885ALDH1A1 3923/4885KDM5A 508/4885
US-20140235616-A1 PYRAZOLOQUINOLINONE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF CYP11B2, CYP1A2, COQ8A KDM4E 3756/4885ALDH1A1 97/4885KDM5A 2819/4885
US-10323018-B2 Quinazoline and quinoline compounds and uses thereof NAMPT, NQO2, NNMT KDM4E 582/4885ALDH1A1 2122/4885KDM5A 1320/4885
US-20250325687-A1 CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST TLR3, TLR7, TLR8 KDM4E 4052/4885ALDH1A1 3336/4885KDM5A 3664/4885
US-20180009784-A1 QUINAZOLINE AND QUINOLINE COMPOUNDS AND USES THEREOF NAMPT, NQO2, NNMT KDM4E 582/4885ALDH1A1 2122/4885KDM5A 1320/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.